{"id":"NCT02858037","sponsor":"International Partnership for Microbicides, Inc.","briefTitle":"Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women","officialTitle":"A Phase 3B Open-Label Follow-on Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-18","primaryCompletion":"2018-10-10","completion":"2018-10-10","firstPosted":"2016-08-08","resultsPosted":"2022-10-25","lastUpdate":"2022-10-25"},"enrollment":1456,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Human Immunodeficiency Virus"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Dapivirine Vaginal Ring","otherNames":[]}],"arms":[{"label":"HIV Open-label Prevention","type":"EXPERIMENTAL"}],"summary":"HIV Open-label Prevention Extension (HOPE).","primaryOutcome":{"measure":"The Safety Profile Associated With the Open-label Use of the Dapivirine Vaginal Matrix Ring (25 mg) in Women","timeFrame":"13 months","effectByArm":[{"arm":"HIV Open-label Prevention","deltaMin":52,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["Malawi","South Africa","Uganda","Zimbabwe"]},"refs":{"pmids":["33539762","32920652"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":19,"n":1368},"commonTop":["Genitourinary chlamydia infection","Vaginal discharge","Vulvovaginitis trichomonal","Urinary Tract Infection","Bacteria vaginosis"]}}